MX2023006568A - Metodo para el diagnostico de las enfermedades amiloideas. - Google Patents
Metodo para el diagnostico de las enfermedades amiloideas.Info
- Publication number
- MX2023006568A MX2023006568A MX2023006568A MX2023006568A MX2023006568A MX 2023006568 A MX2023006568 A MX 2023006568A MX 2023006568 A MX2023006568 A MX 2023006568A MX 2023006568 A MX2023006568 A MX 2023006568A MX 2023006568 A MX2023006568 A MX 2023006568A
- Authority
- MX
- Mexico
- Prior art keywords
- amyloid diseases
- diagnosing amyloid
- diagnosing
- methods
- amyloid
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 206010002022 amyloidosis Diseases 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Optics & Photonics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medical Treatment And Welfare Office Work (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063121779P | 2020-12-04 | 2020-12-04 | |
| PCT/US2021/072729 WO2022120378A1 (en) | 2020-12-04 | 2021-12-03 | Method for diagnosing amyloid diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023006568A true MX2023006568A (es) | 2023-06-16 |
Family
ID=79170797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023006568A MX2023006568A (es) | 2020-12-04 | 2021-12-03 | Metodo para el diagnostico de las enfermedades amiloideas. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240003912A1 (https=) |
| EP (1) | EP4255508A1 (https=) |
| JP (1) | JP2023553877A (https=) |
| KR (1) | KR20230144525A (https=) |
| CN (1) | CN117460543A (https=) |
| AU (1) | AU2021393591A1 (https=) |
| CA (1) | CA3200167A1 (https=) |
| IL (1) | IL302834A (https=) |
| MX (1) | MX2023006568A (https=) |
| WO (1) | WO2022120378A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025212955A1 (en) * | 2024-04-05 | 2025-10-09 | University Of Tennessee Research Foundation | Method for diagnosing amyloid diseases |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| US4900540A (en) | 1983-06-20 | 1990-02-13 | Trustees Of The University Of Massachusetts | Lipisomes containing gas for ultrasound detection |
| EP0231091B1 (en) | 1986-01-24 | 1993-03-31 | Children's Hospital Medical Center | Stable emulsions of highly fluorinated organic compound |
| MX9205298A (es) | 1991-09-17 | 1993-05-01 | Steven Carl Quay | Medios gaseosos de contraste de ultrasonido y metodo para seleccionar gases para usarse como medios de contraste de ultrasonido |
| US10213506B2 (en) * | 2014-08-26 | 2019-02-26 | University Of Tennessee Research Foundation | Targeting immunotherapy for amyloidosis |
| EP4058479A4 (en) * | 2019-11-15 | 2024-02-28 | University of Tennessee Research Foundation | MODIFIED IMMUNOLOBULINES FOR TARGETING AMYLOID DEPOSITS |
| AU2021208630A1 (en) * | 2020-01-17 | 2022-07-21 | University Of Tennessee Research Foundation | Chimeric antigen receptors for removal of amyloid |
-
2021
- 2021-12-03 WO PCT/US2021/072729 patent/WO2022120378A1/en not_active Ceased
- 2021-12-03 US US18/039,949 patent/US20240003912A1/en active Pending
- 2021-12-03 CA CA3200167A patent/CA3200167A1/en active Pending
- 2021-12-03 EP EP21835563.4A patent/EP4255508A1/en active Pending
- 2021-12-03 AU AU2021393591A patent/AU2021393591A1/en active Pending
- 2021-12-03 JP JP2023533877A patent/JP2023553877A/ja active Pending
- 2021-12-03 IL IL302834A patent/IL302834A/en unknown
- 2021-12-03 CN CN202180079752.XA patent/CN117460543A/zh active Pending
- 2021-12-03 MX MX2023006568A patent/MX2023006568A/es unknown
- 2021-12-03 KR KR1020237022487A patent/KR20230144525A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4255508A1 (en) | 2023-10-11 |
| IL302834A (en) | 2023-07-01 |
| AU2021393591A9 (en) | 2024-10-03 |
| CN117460543A (zh) | 2024-01-26 |
| JP2023553877A (ja) | 2023-12-26 |
| US20240003912A1 (en) | 2024-01-04 |
| WO2022120378A1 (en) | 2022-06-09 |
| AU2021393591A1 (en) | 2023-07-06 |
| KR20230144525A (ko) | 2023-10-16 |
| CA3200167A1 (en) | 2022-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020009991A (es) | Metodos basados en anticuerpos para detectar y tratar la enfermedad de alzheimer. | |
| MX2020009140A (es) | Metodos para el tratamiento de enfermedades oculares. | |
| MX2020011458A (es) | Metodos de diagnostico y tratamiento basados en fosforilacion de tau especifica del sitio. | |
| Valcárcel-Nazco et al. | Cost-effectiveness of the use of biomarkers in cerebrospinal fluid for Alzheimer's disease | |
| EP3866687A4 (en) | METHOD AND DEVICE FOR DIAGNOSIS OF DISEASES FROM PATIENT NOISE | |
| WO2020104705A3 (en) | Predicting a treatment response in inflammatory bowel disease | |
| EP4497376A3 (en) | Devices and methods for treating cancer and cardiac wasting | |
| CY1120175T1 (el) | Ανταγωνιστες υποδοχεα clever-1 για αποκλεισμο των ανοσο-ανασταλτικων μακροφαγων τυπου 2 | |
| MX2023006568A (es) | Metodo para el diagnostico de las enfermedades amiloideas. | |
| MX2022001089A (es) | Metodo para identificar al paciente sensible a farmacos de carbohidratos en pacientes que tienen enfermedad de alzheimer. | |
| CO2022010592A2 (es) | Métodos de tratamiento de la esplenomegalia | |
| AR076041A1 (es) | Biomarcadores de proteina para el diagnostico de enfermedades de tejido blando y como objetivos terapeuticos para intervenciones de cuidado oral | |
| GB202406210D0 (en) | Treatment methods for als patients | |
| MY209272A (en) | Use of anti-pd-1 antibody in preparation of medicament for treating solid tumors | |
| MX2022003101A (es) | Metodos de tratamiento de enfermedades oculares. | |
| EP3911348A4 (en) | METHODS OF TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES | |
| GB2603806B (en) | A method of identifying an isocenter | |
| Moreau et al. | Anxiety and coping strategy changes in multiple sclerosis patients initiating fingolimod: the GRACE prospective study | |
| RU2013122853A (ru) | Биомаркер для болезни альцгеймера или умеренного когнитивного расстройства | |
| Hunter et al. | Gender-specific sensitivity to low frequencies in male speech | |
| MX2024005926A (es) | Tratamiento de pacientes con liposarcoma mixoide/de celulas redondas. | |
| KR102641554B9 (ko) | 반려동물 질병 진단장치 및 방법 | |
| WO2019004748A3 (ko) | 페리오스틴을 이용한 아이소사이아네이트 직업성 천식의 진단방법 | |
| Wood | Stem cell implants show promise in chronic traumatic brain injury | |
| GB2605987B (en) | Methods and kits for diagnosing COVID-19 disease |